IGM Biosciences, Inc. (IGMS)
Largest Insider Buys in Sector
IGMS Stock Price History Chart
IGMS Stock Performance
About IGM Biosciences, Inc.
IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non-Hodgkin's lymphoma (NHL). It is also developing IGM-8444, an IgM antibody, which is in Phase 1 clinical trials for the treatment of patients with solid cancers; and IGM-7354, an anti-PD-L1 IgM antibody for the treatment of patients with solid and hematologic malignancies; IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of patients with multiple myeloma; and IGM-2537, a bispecific T cell engaging IgM antibody targeting CD123 and CD3 proteins for the treatment of patients with acute myeloid leukemia, myelodysplastic syndromes, and acute lymphoblastic leukemia. It has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.
Insider Activity of IGM Biosciences, Inc.
Over the last 12 months, insiders at IGM Biosciences, Inc. have bought $6.86M and sold $881,039 worth of IGM Biosciences, Inc. stock.
On average, over the past 5 years, insiders at IGM Biosciences, Inc. have bought $45.43M and sold $1.96M worth of stock each year.
Highest buying activity among insiders over the last 12 months: BAKER BROS. ADVISORS LP () — $116.57M.
The last purchase of 97,473 shares for transaction amount of $937,632 was made by BAKER BROS. ADVISORS LP () on 2024‑03‑28.
List of Insider Buy and Sell Transactions, IGM Biosciences, Inc.
| 2024-09-13 | Sale | CEO AND PRESIDENT | 3,946 0.0062% | $11.54 | $45,532 | +17.89% | ||
| 2024-09-13 | Sale | CHIEF SCIENTIFIC OFFICER | 1,487 0.0023% | $11.54 | $17,158 | +17.89% | ||
| 2024-09-13 | Sale | Head, Research & Autoimmunity | 1,487 0.0023% | $11.54 | $17,158 | +17.89% | ||
| 2024-09-13 | Sale | CHIEF MEDICAL OFFICER | 1,487 0.0023% | $11.54 | $17,158 | +17.89% | ||
| 2024-09-13 | Sale | CHIEF FINANCIAL OFFICER | 1,487 0.0023% | $11.54 | $17,158 | +17.89% | ||
| 2024-09-13 | Sale | CHIEF BUSINESS OFFICER | 925 0.0015% | $11.54 | $10,673 | +17.89% | ||
| 2024-09-13 | Sale | PRINCIPAL ACCOUNTING OFFICER | 469 0.0007% | $11.54 | $5,412 | +17.89% | ||
| 2024-07-25 | Sale | director | 15,132 0.0297% | $14.00 | $211,848 | -7.60% | ||
| 2024-06-14 | Sale | CEO AND PRESIDENT | 4,164 0.0067% | $7.58 | $31,544 | +48.35% | ||
| 2024-06-14 | Sale | CHIEF SCIENTIFIC OFFICER | 1,106 0.0018% | $7.58 | $8,378 | +48.35% | ||
| 2024-06-14 | Sale | CHIEF MEDICAL OFFICER | 1,570 0.0025% | $7.58 | $11,893 | +48.35% | ||
| 2024-06-14 | Sale | CHIEF FINANCIAL OFFICER | 1,570 0.0025% | $7.58 | $11,893 | +48.35% | ||
| 2024-06-14 | Sale | Head, Research & Autoimmunity | 1,570 0.0025% | $7.58 | $11,893 | +48.35% | ||
| 2024-06-14 | Sale | CHIEF BUSINESS OFFICER | 977 0.0016% | $7.58 | $7,401 | +48.35% | ||
| 2024-06-14 | Sale | PRINCIPAL ACCOUNTING OFFICER | 495 0.0008% | $7.58 | $3,750 | +48.35% | ||
| 2024-03-28 | 97,473 0.1653% | $9.62 | $937,632 | +0.83% | ||||
| 2024-03-27 | 27,844 0.0472% | $9.24 | $257,170 | +4.42% | ||||
| 2024-03-26 | 270,000 0.4372% | $8.26 | $2.23M | +11.58% | ||||
| 2024-03-14 | Sale | CEO AND PRESIDENT | 4,182 0.0073% | $10.17 | $42,533 | -3.77% | ||
| 2024-03-14 | Sale | CHIEF SCIENTIFIC OFFICER | 1,844 0.0032% | $10.17 | $18,754 | -3.77% |
Insider Historical Profitability
| BAKER BROS. ADVISORS LP | 3753480 6.3122% | $10.37 | 7 | 0 | ||
| Schwarzer Fred | CEO AND PRESIDENT | 250124 0.4206% | $10.37 | 0 | 10 | |
| Keyt Bruce | CHIEF SCIENTIFIC OFFICER | 242948 0.4086% | $10.37 | 0 | 31 | |
| Harler Mary Beth | Head, Research & Autoimmunity | 163740 0.2754% | $10.37 | 0 | 2 | |
| Takimoto Chris H | CHIEF MEDICAL OFFICER | 154331 0.2595% | $10.37 | 0 | 10 | |
| Tahir Misbah | CHIEF FINANCIAL OFFICER | 122694 0.2063% | $10.37 | 0 | 11 | |
| Decker Lisa Lynn | CHIEF BUSINESS OFFICER | 79104 0.133% | $10.37 | 0 | 11 | |
| Weber Steven | PRINCIPAL ACCOUNTING OFFICER | 25543 0.043% | $10.37 | 0 | 4 | |
| Hambleton Julie | director | 2000 0.0034% | $10.37 | 1 | 3 | +104.4% |
| Topsoe Holding A/S | 10 percent owner | 5044295 8.4829% | $10.37 | 4 | 0 | +25.62% |
| Green Jeremy | 4500225 7.568% | $10.37 | 1 | 0 | <0.0001% | |
| Redmile Group, LLC | director | 2974186 5.0016% | $10.37 | 7 | 1 | +49.57% |
| Baker Brothers Life Sciences LP | 421532 0.7089% | $10.37 | 1 | 0 | <0.0001% | |
| BEHRENS M KATHLEEN | director | 330700 0.5561% | $10.37 | 7 | 0 | +23.89% |
| Chen Daniel ShinYu | Chief Medical Officer | 116518 0.1959% | $10.37 | 0 | 15 | |
| Topsoe Jakob Haldor | 81644 0.1373% | $10.37 | 10 | 0 | +42.2% | |
| Gauthier George | Chief Commercial Officer | 39642 0.0667% | $10.37 | 0 | 9 | |
| LOBERG MICHAEL D | director | 35305 0.0594% | $10.37 | 5 | 0 | +0.84% |
| Topsoe Christina Teng | 9800 0.0165% | $10.37 | 6 | 0 | +19.55% |
Institutional Investor Ownership
| Baker Bros Advisors LP | $39.45M | 6.93 | 4.09M | +10.76% | +$3.83M | 0.28 | |
| T. Rowe Price | $37.52M | 6.59 | 3.89M | +19.26% | +$6.06M | 0.01 | |
| Artal Group S A | $29.73M | 5.22 | 3.08M | -0.65% | -$193,000.00 | 0.13 | |
| Redmile Group | $29.65M | 5.21 | 3.07M | +3.4% | +$974,032.41 | 0.3 | |
| Fidelity Investments | $12.71M | 2.23 | 1.32M | -22.44% | -$3.68M | <0.01 | |
| Goldman Sachs | $12.34M | 2.17 | 1.28M | +22.88% | +$2.3M | <0.01 | |
| RA Capital Management, L.P. | $9.05M | 1.59 | 937,500 | 0% | +$0 | 0.01 | |
| The Vanguard Group | $8.24M | 1.45 | 853,658 | -4.85% | -$419,688.16 | <0.0001 | |
| BlackRock | $7.31M | 1.28 | 757,963 | -0.59% | -$43,492.56 | <0.0001 | |
| Millennium Management LLC | $6.71M | 1.18 | 695,061 | +181.18% | +$4.32M | <0.01 | |
| Geode Capital Management | $3.24M | 0.57 | 336,005 | +2.86% | +$90,228.58 | <0.0001 | |
| State Street | $3.08M | 0.54 | 319,269 | +3.84% | +$113,879.66 | <0.0001 | |
| RHENMAN & PARTNERS ASSET MANAGEMENT AB | $1.88M | 0.33 | 195,000 | -2.5% | -$48,250.00 | 0.18 | |
| Td Asset Management Inc | $1.54M | 0.27 | 159,122 | +90.67% | +$730,215.36 | <0.01 | |
| Samsara Biocapital Llc | $1.49M | 0.26 | 154,664 | 0% | +$0 | 0.23 | |
| Northern Trust | $1.32M | 0.23 | 137,236 | +0.32% | +$4,246.00 | <0.0001 | |
| Charles Schwab | $1.17M | 0.21 | 121,118 | +0.25% | +$2,904.65 | <0.0001 | |
| Morgan Stanley | $975,568.00 | 0.17 | 101,095 | +6.37% | +$58,421.18 | <0.0001 | |
| D. E. Shaw & Co. | $899,023.00 | 0.16 | 93,163 | +97.19% | +$443,108.72 | <0.01 | |
| Jacobs Levy Equity Management | $758,297.00 | 0.13 | 78,580 | New | +$758,297.00 | <0.01 | |
| Woodline Partners LP | $723,750.00 | 0.13 | 75,000 | 0% | +$0 | 0.01 | |
| Marshall Wace | $682,988.00 | 0.12 | 70,776 | New | +$682,988.00 | <0.01 | |
| The Manufacturers Life Insurance Company | $680,335.00 | 0.12 | 70,501 | +44.05% | +$208,044.46 | <0.01 | |
| Pennant Capital Management Llc | $626,285.00 | 0.11 | 64,900 | 0% | +$0 | 0.1 | |
| Bruce Co Inc | $627,250.00 | 0.11 | 65,000 | 0% | +$0 | 0.26 | |
| Wellington Management Company | $551,884.00 | 0.1 | 57,190 | New | +$551,884.00 | <0.0001 | |
| BNY Mellon | $478,186.00 | 0.08 | 49,553 | -4.7% | -$23,584.58 | <0.0001 | |
| Renaissance Technologies | $464,000.00 | 0.08 | 48,100 | +31.42% | +$110,935.55 | <0.01 | |
| Eagle Bay Advisors Llc | $430,728.00 | 0.08 | 44,635 | 0% | +$0 | 0.28 | |
| Nuveen | $393,228.00 | 0.07 | 40,749 | -18.21% | -$87,564.13 | <0.0001 | |
| Dimensional Fund Advisors | $380,722.00 | 0.07 | 39,453 | 0% | +$0 | <0.0001 | |
| AllianceBernstein | $311,695.00 | 0.06 | 32,300 | 0% | +$0 | <0.0001 | |
| Jane Street Capital | $300,308.00 | 0.05 | 31,120 | -12.67% | -$43,569.75 | <0.0001 | |
| Exchange Traded Concepts, LLC | $269,573.00 | 0.05 | 27,935 | +46.66% | +$85,759.63 | 0.01 | |
| Susquehanna Fundamental Investments Llc | $267,604.00 | 0.05 | 27,731 | New | +$267,604.00 | 0.01 | |
| Trexquant Investment LP | $233,308.00 | 0.04 | 24,177 | New | +$233,308.00 | <0.01 | |
| Panagora | $225,028.00 | 0.04 | 23,319 | -22.97% | -$67,106.00 | <0.01 | |
| Bank of America | $214,924.00 | 0.04 | 22,272 | -9.95% | -$23,738.91 | <0.0001 | |
| ExodusPoint Capital Management, LP | $196,000.00 | 0.03 | 20,323 | New | +$196,000.00 | <0.01 | |
| Walleye Capital | $193,483.00 | 0.03 | 20,050 | New | +$193,483.00 | <0.01 | |
| RhumbLine Advisers | $193,870.00 | 0.03 | 20,091 | +4.62% | +$8,559.19 | <0.0001 | |
| Barclays | $184,000.00 | 0.03 | 19,054 | -22.45% | -$53,266.72 | <0.0001 | |
| Gsa Capital Partners Llp | $178,000.00 | 0.03 | 18,398 | New | +$178,000.00 | 0.01 | |
| American Century Investments | $165,083.00 | 0.03 | 17,107 | New | +$165,083.00 | <0.0001 | |
| Two Sigma | $167,283.00 | 0.03 | 17,335 | New | +$167,283.00 | <0.0001 | |
| Virtus ETF Advisers LLC | $128,654.00 | 0.02 | 13,332 | -6.4% | -$8,791.16 | 0.04 | |
| UBS | $128,644.00 | 0.02 | 13,331 | +0.99% | +$1,264.15 | <0.0001 | |
| Citadel Advisors LLC | $127,023.00 | 0.02 | 13,163 | -93.78% | -$1.91M | <0.0001 | |
| Xtx Topco Ltd | $115,231.00 | 0.02 | 11,941 | New | +$115,231.00 | <0.01 | |
| Pale Fire Capital Se | $111,950.00 | 0.02 | 11,601 | 0% | +$0 | <0.01 |